Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis

November 16, 2025 updated by: salih tan, Istanbul Medipol University Hospital
Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients with Bronchiectasis between the ages of 30-55

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Investigating the effect of yoga training on functional capacity and quality of life and comparing with previous studies

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye), 34000
        • Istanbul Medipol University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

30 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosed with bronchiectasis
  • Age 30-55
  • Not having a known systemic, orthopedic or neurological disease

Exclusion Criteria:

  • Severe heart failure
  • People who had an acute exacerbation up to three weeks ago will not be included in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Yoga Training Group

Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session.

During the program, the perceived fatigue intensity of the patients will be questioned with the Modified Borg Scale.

Yoga Session

1-8 weeks and duration

  • Breathing Exercises 5 min
  • Instant Relaxation Technique 2 min
  • Warm-up Exercises 10 min
  • Quick Relaxation Technique 3 min
  • Asanas (Posture Exercises) 15 min
  • Alternative Breathing Exercises 10 min
  • Deep Relaxation Technique 3 min
Other: Yoga Training Program (exercises)
Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
No Intervention: Control group

Training: The exercise program will include respiration exercises that they can do at home.

Before the exercise program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters and tests used in the evaluation. Respiratory control, breathing exercises, relaxation techniques and the reasons, importance and effects of exercise training in the treatment program will be explained.

Breathing Exercises (10 min) Pursed-lip breathing training, Chest breathing exercise (10 repetitions), Diaphragmatic breathing exercise (10 repetitions), Bilateral basal expansion breathing exercises (10 repetitions)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Patient Follow-up Form
Time Frame: Baseline
The demographic characteristics, physical characteristics such as age, height and body weight of the individuals included in the study and their education status will be recorded.
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Dyspnea Assessment
Time Frame: Before and after treatment (8 week)

Dyspnea will be assessed by the modified Medical Research Council (MMRC) dyspnea scale. Individuals will be asked to choose the statement that best describes their dyspnea level.

Scoring in MMRC varies between 0-4 points. "0 points" means that there is no dyspnea; "4 points" indicates a perception of dyspnea during basic daily life activities such as dressing.
Before and after treatment (8 week)

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Respiratory Function Test
Time Frame: Before and after treatment( 8 week )
A spirometer will be used to evaluate the lung function of individuals. It will be expressed as a percentage of the expected values by age, height, body weight and gender.
Before and after treatment( 8 week )
Quality of Life Assessment
Time Frame: Before and after treatment (8 week)

Quality of life, St. George's Respiratory Questionnaire (SGRQ). SGRQ is a health-related quality of life questionnaire that questions a total of 50 items under 3 main components: symptoms (8 items), activity (16 items) and effects of disease (26 items). The symptoms component includes the frequency and duration of symptoms such as cough, sputum, shortness of breath, wheezing.

The activity component relates to physical activities that are restricted due to shortness of breath. It includes factors such as the effects component of the disease, the drugs used and its side effects, the individual's expectations for health and the discomfort they face in daily life. The total score is between 0-100. The higher the score, the lower the quality of life
Before and after treatment (8 week)
Evaluation of Functional Capacity
Time Frame: Before and after treatment (8 week)

Individuals' functional capacity will be evaluated with the six-minute walking test (6MWT). During the 6MWT, individuals are asked to walk in a straight corridor of 30 meters as fast as possible, at their own walking pace in standard directions.

At the end of the test, the walking distance is recorded in meters.
Before and after treatment (8 week)
Assessment of Sleep Quality
Time Frame: Before and after treatment (8 week)

Pittsburgh Sleep Quality Index (PSQI) will be used to evaluate the sleep quality of the individuals participating in our study before and after the 8-week study period.

PSQI is a test that plays a role in determining sleep quality and sleep-related disorders in the last month. It is a scale consisting of 19 self-report items, a total of 24 questions with a score range of 0-21, and the remaining five questions must be answered by a roommate or a spouse. It is a test that evaluates a wide variety of areas related to sleep quality, including components, sleep time, delays in falling asleep, the frequency and severity of sleep-related problems, and the impact of poor sleep on an individual's work.
Before and after treatment (8 week)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Medipol University Hospital

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Salih Tan, Istanbul Medipol University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 25, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 20, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 21, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 5, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 8, 2021

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 18, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 16, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 10840098-604.01.01-E.19408

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bronchiectasis Adult

Clinical Trials on Yoga Training Program (exercises)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings